Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nektar Therapeutics, a biopharmaceutical company developing new therapeutics based on its PEGylation and advanced polymer conjugation technology platforms, has reported revenues $42.6m for the second quarter ended June 30, 2010 compared to $13m for the comparable period in 2009.
Subscribe to our email newsletter
Nektar Therapeutics has posted a net loss of $517m for the second quarter 2010, or $0.01 loss per diluted share, compared to net loss of $32.1m, or $0.35 loss per diluted share, for the comparable period in 2009.
For the six months ended June 30, 2010, Nektar Therapeutics has posted revenue of $75.8m compared to $22.7m for the year ago period.
A net loss of $6.65m, or $0.07 loss per diluted share, compared to $63.9m, or $0.7 loss per diluted share, for the year ago period.
Howard Robin, president and CEO of Nektar Therapeutics, said: “The number of drug candidates advanced by Nektar in just three years highlights the potential of our polymer conjugation technology to create a steady stream of product opportunities.
“In the second quarter, we reported compelling Phase 2 data for our oncology compound, NKTR-102, in both ovarian and breast cancer patients.”